REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 218 filers reported holding REATA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,271,078 | +280.1% | 41,890 | +238.9% | 0.01% | +250.0% |
| Q1 2023 | $1,123,797 | +38.0% | 12,361 | -42.3% | 0.00% | 0.0% |
| Q4 2022 | $814,283 | +9.2% | 21,426 | +195.9% | 0.00% | 0.0% |
| Q3 2021 | $746,000 | -30.3% | 7,241 | -1.3% | 0.00% | 0.0% |
| Q2 2021 | $1,071,000 | +28.3% | 7,336 | -3.2% | 0.00% | 0.0% |
| Q1 2021 | $835,000 | -13.3% | 7,577 | -4.2% | 0.00% | 0.0% |
| Q4 2020 | $963,000 | +110.7% | 7,908 | +67.8% | 0.00% | +100.0% |
| Q3 2020 | $457,000 | -40.4% | 4,714 | -4.1% | 0.00% | -50.0% |
| Q2 2020 | $767,000 | -6.6% | 4,918 | -13.7% | 0.00% | -33.3% |
| Q1 2020 | $821,000 | -15.4% | 5,702 | +20.2% | 0.00% | 0.0% |
| Q4 2019 | $971,000 | +96.6% | 4,742 | -10.1% | 0.00% | +50.0% |
| Q2 2019 | $494,000 | -22.2% | 5,275 | -29.4% | 0.00% | 0.0% |
| Q1 2019 | $635,000 | +30.7% | 7,467 | -13.8% | 0.00% | 0.0% |
| Q4 2018 | $486,000 | – | 8,665 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |